Biography
Douglas K. Graham, MD, PhD, is the chief and William G. Woods, MD Chair of the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta. Dr. Graham also serves as chief of the Division of Pediatric Hematology/Oncology/BMT. Board certified in pediatric hematology/oncology, his clinical focus is in pediatric leukemia.
Prior to joining the Aflac Cancer Center, Dr. Graham previously served as professor of pediatrics and immunology at the University of Colorado, with clinical practice at Children's Hospital Colorado. While there, Dr. Graham led the Biology and Treatment of Childhood Cancer Research Emphasis Area for the hospital. He directly oversaw all basic science, translational and clinical oncology research for the hospital.
Dr. Graham is a National Institutes of Health-funded investigator with an active laboratory focusing on developing novel therapeutics for pediatric cancer, recently validating MerTK as a novel cancer agent in leukemia, melanoma, non-small cell lung cancer and glioblastoma. He was the co-program leader of the Hematologic Malignancy Program at the University of Colorado, a National Cancer Institute-designated cancer center.
Dr. Graham is a member of the Children's Oncology Group, COG Acute Myeloid Leukemia Disease Committee and the NIH Molecular and Cellular Hematology Study Section. He also holds memberships with American Society of Pediatric Hematology/Oncology, American Society of Hematology, American Society for Cancer Research, American Society for Clinical Investigation, Society for Pediatric Research and American Academy of Pediatrics.
Education
Dr. Graham received his Medical Degree as well as his PhD in Microbiology and Immunology from University of North Carolina in Chapel Hill, NC. He completed his residency in pediatrics and a fellowship in pediatric hematology/oncology at University of Colorado at Denver.
Titles & Roles
-
Chief and William G. Woods, M.D. ChairAflac Cancer and Blood Disorders Center
-
Professor, Department of PediatricsEmory University School of Medicine
-
Chief, Division of Pediatric Hematology/Oncology/BMTEmory University School of Medicine
Research
Dr. Graham's lab is actively conducting research studying tyrosine kinase signaling pathways in cancer. In particular, his lab studies the Mer and Axl pathways in pediatric leukemia and pediatric brain cancer. They also study the role of these pathways in melanoma and non-small cell lung cancer. His laboratory is working to develop novel inhibitors of these pathways to hopefully move forward into clinical trials in the near future.
Grants
| Grant Number | Title |
|---|---|
| 1R01CA259077-01 | Novel TYRO3 inhibitors for treatment of cancer |
| 1R01CA276135-01A1 | Discovery of a novel MDM2-tubulin signaling pathway as a therapeutic target in AML |
| 5R01CA249190-05 | MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity |
| 5R01CA259077-02 | Novel TYRO3 inhibitors for treatment of cancer |
| 5R01CA259077-03 | Novel TYRO3 inhibitors for treatment of cancer |
| 5R01CA259077-04 | Novel TYRO3 inhibitors for treatment of cancer |
| 5R01CA259077-05 | Novel TYRO3 inhibitors for treatment of cancer |
| 5R01CA276135-02 | Discovery of a novel MDM2-tubulin signaling pathway as a therapeutic target in AML |